ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Increased Water Intake in Chronic Kidney Disease (WIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01766687
Recruitment Status : Completed
First Posted : January 11, 2013
Last Update Posted : August 25, 2017
Sponsor:
Collaborator:
Danone Research
Information provided by (Responsible Party):
William Clark, Lawson Health Research Institute

January 9, 2013
January 11, 2013
August 25, 2017
April 2013
June 2017   (Final data collection date for primary outcome measure)
Renal decline [ Time Frame: Baseline and 12 months ]
Change in estimated glomerular filtration rate between baseline and 12 months
Same as current
Complete list of historical versions of study NCT01766687 on ClinicalTrials.gov Archive Site
  • 24-hour urine albumin [ Time Frame: Baseline and 12 months ]
    Change in 24-hour urine albumin between baseline and 12 months
  • Rapid renal decline [ Time Frame: Baseline and 12 months ]
    Proportion with eGFR (estimated glomerular filtration rate) decline >5% between baseline and 12 months
  • Measured creatinine clearance [ Time Frame: Baseline and 12 months ]
    Change in measured creatinine clearance between baseline and 12 months
  • Health-related quality of life [ Time Frame: Baseline and 12 months ]
    Change in health-related quality of life between baseline and 12 months
  • Copeptin [ Time Frame: Baseline and 12 months ]
    Change in copeptin between baseline and 12 months
  • albumin to creatinine ratio [ Time Frame: Baseline and 12 months ]
    Change in albumin to creatinine ratio between baseline and 12 months
  • Rapid renal decline [ Time Frame: Baseline and 12 months ]
    Proportion with eGFR (estimated glomerular filtration rate) decline >5% between baseline and 12 months
  • Body Mass Index [ Time Frame: Baseline and 12 months ]
    Change in Body Mass Index between baseline and 12 months
  • Blood pressure [ Time Frame: Baseline and 12 months ]
    Change in mean arterial blood pressure between baseline and 12 months
  • HbA1c [ Time Frame: Baseline and 12 months ]
    Change in HbA1c between between baseline and 12 months
  • Long-term renal decline [ Time Frame: Baseline and 24 months ]
    Change in estimated glomerular filtration rate between baseline and 24 months
  • Effect of fluid coaching on adherence [ Time Frame: 12 and 24 months ]
    Change in urine volume between 12 months and 24-months follow-up
  • Body Mass Index [ Time Frame: Baseline and 12 months ]
    Change in Body Mass Index between baseline and 12 months
  • Blood pressure [ Time Frame: Baseline and 12 months ]
    Change in mean arterial blood pressure between baseline and 12 months
  • Copeptin [ Time Frame: Baseline and 12 months ]
    Change in copeptin between baseline and 12 months
  • HbA1c [ Time Frame: Baseline and 12 months ]
    Change in HbA1c between between baseline and 12 months
 
Impact of Increased Water Intake in Chronic Kidney Disease
A Randomized Controlled Trial of Increased Water Intake in Chronic Kidney Disease
The investigators have designed a randomized controlled trial to test whether increased water intake slows renal decline in patients with Stage-III Chronic Kidney Disease. Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual fluid intake, for one year. The investigators will calculate the change in kidney function (estimated glomerular filtration rate, measured every three months for 12 months), and compare renal decline between the intervention and control groups. The investigators hypothesize that increased water intake will slow renal decline.
Not Provided
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:
Research staff and participants were aware of the randomized group assignment; however, outcome assessors (technicians performing the laboratory measurements for the primary and secondary outcomes) are blinded to the random allocation, and the trial statistician will be blinded to patient allocation for the primary analysis
Primary Purpose: Treatment
Chronic Kidney Disease
Dietary Supplement: Hydration
  • Experimental: Hydration
    Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
    Intervention: Dietary Supplement: Hydration
  • No Intervention: Control

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
822
700
June 2017
June 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-80 years
  • Able to provide informed consent and willing to complete follow-up visits.
  • Estimated glomerular filtration rate between 30 and 60 ml/min/1.73m2
  • Trace protein or greater (Albustix) or urine albumin/creatinine ratio >2.8 mg/mmol (if female) or >2.0 mg/mmol (if male) from a random spot urine sample

Exclusion Criteria:

  • Self-reported fluid intake >10 cups/day or 24-hr urine volume >3L.
  • Enrolled in another trial that could influence the intervention, outcomes or data collection of this trial (or previously enrolled in this trial)
  • Received one or more dialysis treatments in the past month
  • Kidney transplant within past six months (or on waiting list)
  • Pregnant or breastfeeding
  • History of kidney stones in past 5 years
  • Less than two years life expectancy
  • Serum sodium <130 mEq/L without suitable explanation
  • Serum calcium >2.6 mmol/L without suitable explanation
  • Currently taking hydrochlorothiazide >25 mg/d, indapamide >1.25 mg/d, furosemide >40 mg, or metolazone >2.5 mg/d
  • Currently taking lithium
  • Patient is under fluid restriction (<1.5 L a day) for kidney disease, heart failure, or liver disease, AND meets any of the following criteria: i) end stage of the disease (heart left ventricular ejection fraction <40%, NYHA class 3 or 4, or end stage cirrhosis) or ii) hospitalization secondary to heart failure, ascites and/or anasarca
  • Patient has GI disease (history of inflammatory bowel disease, Crohns, etc.)
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01766687
S-London RCT
Yes
Not Provided
Not Provided
William Clark, Lawson Health Research Institute
Lawson Health Research Institute
Danone Research
Principal Investigator: William F Clark, MD London Health Sciences Centre
Lawson Health Research Institute
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP